Last reviewed · How we verify
MG1111 (Barycela inj.)
MG1111 is a recombinant human albumin-fused interferon alpha (IFN-α) fusion protein that enhances antiviral and immunomodulatory activity.
MG1111 is a recombinant human albumin-fused interferon alpha (IFN-α) fusion protein that enhances antiviral and immunomodulatory activity. Used for Chronic hepatitis B, Chronic hepatitis C.
At a glance
| Generic name | MG1111 (Barycela inj.) |
|---|---|
| Sponsor | GC Biopharma Corp |
| Drug class | Interferon alpha fusion protein |
| Target | Interferon alpha receptor (IFNAR) |
| Modality | Biologic |
| Therapeutic area | Virology / Immunology |
| Phase | Phase 3 |
Mechanism of action
MG1111 combines human serum albumin with interferon alpha to extend half-life and improve pharmacokinetics while maintaining IFN-α's antiviral and immune-activating properties. The albumin fusion allows for less frequent dosing and potentially improved tolerability compared to conventional interferon formulations. This approach leverages interferon's ability to activate natural killer cells and enhance antiviral immunity.
Approved indications
- Chronic hepatitis B
- Chronic hepatitis C
Common side effects
- Flu-like symptoms (fever, fatigue, myalgia)
- Hematologic abnormalities (thrombocytopenia, leukopenia)
- Elevated liver enzymes
- Depression / neuropsychiatric effects
Key clinical trials
- A Study to Evaluate Immunogenicity and Safety After the First and Second Doses of MG1111 (BARYCELA Inj.) in Healthy Children Aged 12 Months to 12 Years (PHASE3)
- An Open-label, Bridging Study of BARYCELA Inj. in Healthy Vietnamese Children Aged Between 12 Months to 12 Years (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MG1111 (Barycela inj.) CI brief — competitive landscape report
- MG1111 (Barycela inj.) updates RSS · CI watch RSS
- GC Biopharma Corp portfolio CI